We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current BGNE market cap is 18.99B. The company's latest EPS is USD -8.2698 and P/E is -1.74.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 781.31M | 634.41M | 751.65M | 929.17M | 1B |
Operating Income | -133.97M | -383.8M | -261.35M | -107.16M | -120.27M |
Net Income | 215.41M | -367.55M | -251.15M | -120.41M | -121.35M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 428.21M | 308.87M | 1.18B | 1.42B | 2.46B |
Operating Income | -959.89M | -1.66B | -1.44B | -1.79B | -1.21B |
Net Income | -948.63M | -1.6B | -1.41B | -2B | -881.71M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 5.52B | 5.81B | 5.67B | 5.71B | 5.83B |
Total Liabilities | 1.76B | 2.27B | 2.31B | 2.35B | 2.39B |
Total Equity | 3.76B | 3.54B | 3.36B | 3.37B | 3.44B |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.61B | 5.6B | 8.65B | 6.38B | 5.81B |
Total Liabilities | 633.93M | 1.73B | 2.4B | 2B | 2.27B |
Total Equity | 978.36M | 3.87B | 6.24B | 4.38B | 3.54B |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -935.82M | -1.16B | -308.57M | -404.16M | -215.79M |
Investing | 122.59M | 60M | -209.83M | -320.86M | -454.75M |
Financing | 69.43M | 416.48M | 162.29M | 185.31M | 197.97M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -750.27M | -1.28B | -1.3B | -1.5B | -1.16B |
Investing | 554.16M | -3.17B | 640.66M | 1.08B | 60M |
Financing | 85.68M | 5.2B | 3.64B | -18.97M | 416.48M |
Market Cap | 18.99B |
Price to Earnings Ratio | -1.74 |
Price to Sales Ratio | 0.62 |
Price to Cash Ratio | 0.48 |
Price to Book Ratio | 0.43 |
Dividend Yield | - |
Shares Outstanding | 106.62M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 12.96 (6.74%) |
Company Name | BeiGene Ltd |
Address |
94 solaris avenue grand cayman KY1 1104 |
Website | https://www.beigene.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions